重组链激酶Ⅲ期临床试验协作组 中华心血管病杂志 1999 0 27 3


    关键词：心肌梗塞；重组链激酶；血栓溶解疗法 期刊 zhxxgbzz 0 第五次全国心血管病学术会议专栏 fur -->


    

【摘要 】 目的 观察国产重组链激酶在急性心肌梗塞治疗中的溶栓效果和不良反应。方法 自1997年3月～1998年3月间对477例急性心肌梗塞患者予150万单位重组链激酶溶栓治疗，观察溶栓再通率、急性期死亡率、并发症以及不良反应发生率。结果 溶栓再通率为80.2%，35天死亡率5.0%。不良反应中：过敏反应5.5%(26例)，低血压7.8% (37例)，出血15.1% (72例)，1例发生颅内出血但未致残，肝功能损害1.4%(7例)，半月后均恢复。结论 国产重组链激酶为治疗急性心肌梗塞有效、安全的溶栓药物。

Intravenous recombinantstreptokinase on acute myocardial infarction.

    Collaborative Study Group for Multicenter Clinical Trial of Domestic RecombinantStreptokinase Thrombolytic Therapy (Correspondence: ZHU Wenling. Peking Union MedicalCollege Hospital, PUMC & CAMS, Beijing 100730)

【Abstract 】 Objective Toobserve the clinical efficacy and safety of intravenous thrombolytic therapy usingdomestic recombinant streptokinase (rSK) in acute myocardial infarction (AMI). Methods Fourhundred and seventy seven patients, admitted to the multicenter clinical trial groupduring March 1997 to March 1998, were treated by intravenous rSK (1.5MU). The patency ofinfarct-related coronary artery was assessed by unified clinical criteria. Adversereactions were also observed. Results The patency was 80.2%, 35-daymortality was 5%. The rate of allergic reaction was 5.5%. The rate of hypotension was7.8%, of bleeding was 15.1% (including 1 case of nonfatal intracranial hemorrhage). Therate of liver function damage was 1.5%, and all recovered in half a month. Conclusion Domesticrecombinant streptokinase is an effective, reliable and safe thrombolytic agent.

     ......

您现在查看是摘要页，全文长 14735 字符。